HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52

HC Wainwright & Co. analyst Lander Egaña Gorroño has maintained a Buy rating on NeuroSense Therapeutics (NASDAQ: NRSN) and raised the price target significantly from $8 to $52.